Abstract
Background ICU readmissions are associated with increased morbidity, mortality, and healthcare costs. As ICU patient complexity increases and care practices evolve, the contemporary epidemiology of ICU readmissions remains unclear. We aimed to examine ICU readmission rates and timing across multiple health systems, focusing on unplanned readmissions occurring within 24, 48, and 72 hours after ICU discharge. Methods We performed a retrospective cohort study using federated data from the Common Longitudinal ICU data Format (CLIF) Consortium, comprising nine healthcare systems between January 2020 and December 2021 and the MIMIC-IV database. The cohort included adult patients (≥18 years) discharged alive from the ICU. Readmissions following planned surgeries or interventional procedures were excluded. Data were analyzed locally at each site without centralizing patient-level data, and analyses focused on patient demographics, discharge disposition, readmission timing, and clinical interventions during ICU stays and readmissions. Statistical comparisons were performed using two-proportion z-tests and chi-squared tests. Results Among 185,241 hospital admissions across 19 hospitals, 8.6% of ICU discharges were readmitted during the same hospitalization. Unplanned readmissions occurred within 24 hours in 1.9% of cases, 3.4% within 48 hours, and 4.5% within 72 hours. Readmitted patients experienced higher in-hospital mortality (20.6% vs. 2.1%, p<0.001). Compared to the initial ICU stay, ICU readmissions were associated with significantly increased respiratory (42.3% vs. 35.3%, p<0.001) and vasopressor support (26.1% vs. 23.1%, p<0.001). Conclusions ICU readmissions remain common and are linked to worse outcomes. Readmissions require more respiratory and vasopressor support. Future work should focus on characterizing these subphenotypes and improving ICU discharge processes to reduce preventable readmissions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
SA is supported by AHA 25PRE1372516. NI is supported by NIH/NHLBI K23HL166783. CHH is supported by NIH/NHLBI K23HL169743. AB is supported by an institutional research training grant (NIH/T32-HL 00774). ACO is supported by an institutional research training grant (NIH/T32-HL-007891). GEW received support from R35GM155262 relevant to the published work. MS is supposed by NIH UL1TR002378. SVB is supported by NIH/NIGMS K23GM144867. NM is supported by AHA 24PRE1196998 PGL is supported by NIH K08CA270383. WFP is supported by NIH K08HL150291, R01LM014263, and the Greenwall Foundation. YL is supported in part by NIH U01TR003528 and R01LM013337. JCR is supported by NIH/NIDA R01DA051464 and the Searle Funds at The Chicago Community Trust. CAG is supported by NIH/NHLBI K23HL169815, a Parker B. Francis Opportunity Award, and an American Thoracic Society Unrestricted Grant.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this work was granted by the following ethics committees/IRBs: The Institutional Review Board of Oregon Health & Science University gave ethical approval for this work (IRB approval number: 00025188). The Institutional Review Board of the University of Minnesota gave ethical approval for this work (IRB approval number: STUDY00014815). The Institutional Review Board of the University of Michigan gave ethical approval for this work (IRB approval number: HUM00144238). The Institutional Review Board of Northwestern Medicine gave ethical approval for this work (IRB approval number: STU00202840). The Institutional Review Board of the University of Chicago gave ethical approval for this work (IRB approval number: IRB20-1823). The Institutional Review Board of Rush University gave ethical approval for this work (IRB approval number: 20082408-IRB01). The Institutional Review Board of The Johns Hopkins Health System Corporation gave ethical approval for this work (IRB approval number: IRB00421735). The Institutional Review Board of Emory University gave ethical approval for this work (IRB approval number: Study 1815). The Institutional Review Board of the University of Pennsylvania gave ethical approval for this work (IRB approval number: 853717). Each site had waiver of consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos